Diana I. Albu

599 total citations
16 papers, 464 citations indexed

About

Diana I. Albu is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Diana I. Albu has authored 16 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Diana I. Albu's work include Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (5 papers). Diana I. Albu is often cited by papers focused on Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (5 papers). Diana I. Albu collaborates with scholars based in United States, United Kingdom and Singapore. Diana I. Albu's co-authors include Dorina Avram, Neal G. Copeland, Nancy A. Jenkins, Pentao Liu, Danielle Califano, Dongyun Feng, Valeriu B. Cismasiu, Sailaja Ghanta, Hongmei Chen and Javier Duque and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Blood.

In The Last Decade

Diana I. Albu

15 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diana I. Albu United States 8 296 140 107 39 39 16 464
Justine Lopez United States 8 355 1.2× 217 1.6× 133 1.2× 29 0.7× 51 1.3× 11 540
Ludovic Tibor Krausz Italy 7 507 1.7× 123 0.9× 163 1.5× 32 0.8× 73 1.9× 8 633
Ilaria Gori United Kingdom 12 163 0.6× 294 2.1× 77 0.7× 83 2.1× 42 1.1× 17 596
Melba Marie Tejera United States 9 304 1.0× 137 1.0× 163 1.5× 17 0.4× 40 1.0× 9 451
J G I van Rietschoten Netherlands 9 187 0.6× 223 1.6× 116 1.1× 29 0.7× 83 2.1× 11 481
Birgitta Clinchy Sweden 10 193 0.7× 131 0.9× 82 0.8× 16 0.4× 21 0.5× 21 377
Cédric Carli Canada 14 313 1.1× 146 1.0× 145 1.4× 38 1.0× 27 0.7× 20 547
Marika Pla France 9 127 0.4× 184 1.3× 64 0.6× 26 0.7× 35 0.9× 15 375
Andrew Ming‐Lum Canada 8 149 0.5× 185 1.3× 65 0.6× 15 0.4× 47 1.2× 8 376

Countries citing papers authored by Diana I. Albu

Since Specialization
Citations

This map shows the geographic impact of Diana I. Albu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana I. Albu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana I. Albu more than expected).

Fields of papers citing papers by Diana I. Albu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana I. Albu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana I. Albu. The network helps show where Diana I. Albu may publish in the future.

Co-authorship network of co-authors of Diana I. Albu

This figure shows the co-authorship network connecting the top 25 collaborators of Diana I. Albu. A scholar is included among the top collaborators of Diana I. Albu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana I. Albu. Diana I. Albu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Albu, Diana I., Tristan Lubinski, Jason Kong, et al.. (2025). Abstract 7297: Enhanced efficacy of CTX-471, a CD137 agonist antibody, in models of immune checkpoint failure via simultaneous blockade of neo-angiogenesis. Cancer Research. 85(8_Supplement_1). 7297–7297.
2.
Albu, Diana I., Benjamin Wolf, Yan Qin, et al.. (2024). A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. OncoImmunology. 13(1). 2316945–2316945. 2 indexed citations
3.
Albu, Diana I., Xianzhe Wang, Jason Kong, et al.. (2022). Abstract 3431: Dose range finding study in non-human primates confirms the unique mechanism of action of CTX-8371, a novel bispecific antibody blocking PD-1 and PD-L1. Cancer Research. 82(12_Supplement). 3431–3431. 2 indexed citations
4.
5.
Albu, Diana I., David Verbel, Yuan Huang, et al.. (2017). Abstract 4607: Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity. Cancer Research. 77(13_Supplement). 4607–4607. 1 indexed citations
6.
Albu, Diana I., Kuan‐Chun Huang, Jiayi Wu, et al.. (2017). EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology. 6(8). e1338239–e1338239. 71 indexed citations
7.
Bao, Xingfeng, Diana I. Albu, Kuan‐Chun Huang, et al.. (2016). Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology*Biology*Physics. 96(2). S128–S128. 3 indexed citations
8.
Albu, Diana I., Jiayi Wu, Kuan‐Chun Huang, et al.. (2015). Abstract 275: ER-886046, an antagonist of PGE2 receptor type-4, induces an effective antitumor immune response in mice by attenuating intratumoral MDSCs and TAMs. Cancer Research. 75(15_Supplement). 275–275. 3 indexed citations
9.
Bao, Xingfeng, Diana I. Albu, Kuan‐Chun Huang, et al.. (2015). Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models. Journal for ImmunoTherapy of Cancer. 3(S2). 6 indexed citations
10.
Albu, Diana I., Nicole A. Morin, Danielle Califano, et al.. (2011). Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes. Proceedings of the National Academy of Sciences. 108(15). 6211–6216. 36 indexed citations
11.
Albu, Diana I., Danielle Califano, David Jones, et al.. (2011). Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. The Journal of Experimental Medicine. 208(10). 2069–2081. 67 indexed citations
12.
Zhang, Shuning, Raj Kumar Verma, Diana I. Albu, et al.. (2010). Antigen-specific clonal expansion and cytolytic effector function of CD8+ T lymphocytes depend on the transcription factor Bcl11b. The Journal of Experimental Medicine. 207(8). 1687–1699. 44 indexed citations
13.
Albu, Diana I., Danielle Califano, & Dorina Avram. (2010). Flow Cytometry Analysis of Transcription Factors in T Lymphocytes. Methods in molecular biology. 647. 377–390. 11 indexed citations
14.
Albu, Diana I., Dongyun Feng, Nancy A. Jenkins, et al.. (2007). BCL11B is required for positive selection and survival of double-positive thymocytes. The Journal of Experimental Medicine. 204(12). 3003–3015. 107 indexed citations
15.
Cismasiu, Valeriu B., Sailaja Ghanta, Javier Duque, et al.. (2006). BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes. Blood. 108(8). 2695–2702. 76 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justine Lopez Breakdown of academic impact, for papers by Ludovic Tibor Krausz Breakdown of academic impact, for papers by Ilaria Gori Breakdown of academic impact, for papers by Melba Marie Tejera Breakdown of academic impact, for papers by J G I van Rietschoten Breakdown of academic impact, for papers by Birgitta Clinchy Breakdown of academic impact, for papers by Cédric Carli Breakdown of academic impact, for papers by Marika Pla Breakdown of academic impact, for papers by Andrew Ming‐Lum
Rankless by CCL
2026